Literature DB >> 16926572

Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer.

Judy C Boughey1, Florentia Peintinger, Funda Meric-Bernstam, Allison C Perry, Kelly K Hunt, Gildy V Babiera, S E Singletary, Isabelle Bedrosian, Anthony Lucci, Aman U Buzdar, Lajos Pusztai, Henry M Kuerer.   

Abstract

OBJECTIVE: To determine the effect of preoperative chemotherapy on the volume of tissue excised and the number of breast operations in patients undergoing breast-conserving therapy (BCT). SUMMARY BACKGROUND DATA: Preoperative chemotherapy is increasingly being used for breast cancer and increases rates of BCT. Its impact on the extent of surgery and the number of surgical procedures in BCT has never been fully defined. The extent of surgery in BCT directly affects cosmesis.
METHODS: We reviewed the records of 509 consecutive patients with T1-T3, N0-N2 breast cancer who were treated in prospective randomized clinical trials of chemotherapy between 1998 and 2005. We analyzed the final surgical procedure (BCT or mastectomy), the number of operations, and, in patients who underwent BCT, re-excision rates, and the total volume of breast tissue excised [4Pi/3(width/2 x length/2 x height/2)].
RESULTS: A total of 241 patients underwent BCT, and 268 patients underwent mastectomy. Among BCT patients who had initial tumor size >2.0 cm, patients who received preoperative chemotherapy had significantly smaller volumes of breast tissue excised compared with patients who received postoperative chemotherapy (113 cm vs. 213 cm, P = 0.004). The re-excision rate and total number of breast operations did not significantly differ between the groups. Among BCT patients who had initial tumor size < or = 2 cm, preoperative chemotherapy had no impact on volume of breast tissue excised, re-excision rate, or number of breast operations (P > 0.05).
CONCLUSIONS: Among patients treated with BCT for larger breast tumors, patients treated with preoperative chemotherapy have less extensive resection, with no change in rates of re-excision.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16926572      PMCID: PMC1856540          DOI: 10.1097/01.sla.0000234897.38950.5c

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  13 in total

1.  A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility.

Authors:  Lisa A Newman; Aman U Buzdar; S Eva Singletary; Henry M Kuerer; Thomas Buchholz; Frederick C Ames; Merrick I Ross; Kelly K Hunt
Journal:  Ann Surg Oncol       Date:  2002-04       Impact factor: 5.344

2.  Three dimensional staging of breast cancer.

Authors:  I L Wapnir; D E Wartenberg; R S Greco
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.

Authors:  Marjorie C Green; Aman U Buzdar; Terry Smith; Nuhad K Ibrahim; Vicente Valero; Marguerite F Rosales; Massimo Cristofanilli; Daniel J Booser; Lajos Pusztai; Edgardo Rivera; Richard L Theriault; Cynthia Carter; Debra Frye; Kelly K Hunt; W Fraser Symmans; Eric A Strom; Aysegul A Sahin; William Sikov; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

4.  The cosmetic outcome in early breast cancer treated with breast conservation.

Authors:  S K Al-Ghazal; R W Blamey; J Stewart; A A Morgan
Journal:  Eur J Surg Oncol       Date:  1999-12       Impact factor: 4.424

5.  Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.

Authors:  N Wolmark; J Wang; E Mamounas; J Bryant; B Fisher
Journal:  J Natl Cancer Inst Monogr       Date:  2001

6.  Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.

Authors:  J A van der Hage; C J van de Velde; J P Julien; M Tubiana-Hulin; C Vandervelden; L Duchateau
Journal:  J Clin Oncol       Date:  2001-11-15       Impact factor: 44.544

7.  Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma.

Authors:  H M Kuerer; S E Singletary; A U Buzdar; F C Ames; V Valero; T A Buchholz; M I Ross; L Pusztai; G N Hortobagyi; K K Hunt
Journal:  Am J Surg       Date:  2001-12       Impact factor: 2.565

8.  Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.

Authors:  Edwin R Fisher; Jiping Wang; John Bryant; Bernard Fisher; Eletherios Mamounas; Norman Wolmark
Journal:  Cancer       Date:  2002-08-15       Impact factor: 6.860

9.  Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma.

Authors:  D E Wazer; T DiPetrillo; R Schmidt-Ullrich; L Weld; T J Smith; D J Marchant; N J Robert
Journal:  J Clin Oncol       Date:  1992-03       Impact factor: 44.544

10.  Factors influencing cosmetic results after conservation therapy for breast cancer.

Authors:  M E Taylor; C A Perez; K J Halverson; R R Kuske; G W Philpott; D M Garcia; J E Mortimer; R J Myerson; D Radford; C Rush
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-02-15       Impact factor: 7.038

View more
  36 in total

1.  Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer.

Authors:  Antonio Llombart-Cussac; Ángel Guerrero; Antonio Galán; Vicente Carañana; Elvira Buch; Álvaro Rodríguez-Lescure; Amparo Ruiz; Carlos Fuster Diana; Vicente Guillem Porta
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

Review 2.  Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy.

Authors:  Tari A King; Monica Morrow
Journal:  Nat Rev Clin Oncol       Date:  2015-04-07       Impact factor: 66.675

3.  Pathological complete response in breast cancer patients following neoadjuvant chemotherapy at a Comprehensive Cancer Center: The natural history of an elusive prognosticator.

Authors:  Oluwadamilola M Fayanju; Iheoma Nwaogu; Donna B Jeffe; Julie A Margenthaler
Journal:  Mol Clin Oncol       Date:  2015-03-31

4.  Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy.

Authors:  Thomas A Buchholz; Elizabeth A Mittendorf; Kelly K Hunt
Journal:  J Natl Cancer Inst Monogr       Date:  2015-05

Review 5.  Trends and controversies in multidisciplinary care of the patient with breast cancer.

Authors:  Laura S Dominici; Monica Morrow; Elizabeth Mittendorf; Jennifer Bellon; Tari A King
Journal:  Curr Probl Surg       Date:  2016-11-29       Impact factor: 1.909

6.  Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy.

Authors:  Catherine L Akay; Funda Meric-Bernstam; Kelly K Hunt; Elizabeth G Grubbs; Isabelle Bedrosian; Susan L Tucker; Henry M Kuerer; Karen E Hoffman; Gildy V Babiera; Eric A Strom; Thomas A Buchholz; Elizabeth A Mittendorf
Journal:  Ann Surg Oncol       Date:  2011-08-23       Impact factor: 5.344

7.  Multidisciplinary Management of Breast Cancer With Extensive Regional Nodal Involvement.

Authors:  Benjamin D Smith; Matthew P Goetz; Judy C Boughey
Journal:  J Clin Oncol       Date:  2020-05-22       Impact factor: 44.544

Review 8.  Locoregional Management After Neoadjuvant Chemotherapy.

Authors:  Monica Morrow; Atif J Khan
Journal:  J Clin Oncol       Date:  2020-05-22       Impact factor: 44.544

9.  Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy.

Authors:  Elizabeth A Mittendorf; Thomas A Buchholz; Susan L Tucker; Funda Meric-Bernstam; Henry M Kuerer; Ana M Gonzalez-Angulo; Isabelle Bedrosian; Gildy V Babiera; Karen Hoffman; Min Yi; Merrick I Ross; Gabriel N Hortobagyi; Kelly K Hunt
Journal:  Ann Surg       Date:  2013-02       Impact factor: 12.969

10.  Patterns of Regression in Breast Cancer after Primary Systemic Treatment.

Authors:  Tamás Zombori; Gábor Cserni
Journal:  Pathol Oncol Res       Date:  2018-11-27       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.